AccScience Publishing / AN / Online First / DOI: 10.36922/an.378
Submit to AN
Cite this article
96
Download
1637
Views
Journal Browser
Volume | Year
Issue
Search
Forthcoming Issue
Current Issue
View All
News and Announcements
View All
ORIGINAL RESEARCH ARTICLE

Myographic evidence of polymyositis and dermatomyositis in COVID-19 patients

Nareen Haikaz Hasrat1 ,  Haithem Jawad Kadhum1 ,  Zaineb Adil Yakob1 ,  Ali Raheem Hashim2 ,  Hassan Ala Farid3*
Show Less
1 Department of Physiology, College of Medicine, University of Basrah, Basrah, Iraq
2 Department of Medicine, College of Medicine, University of Basrah, Basrah, Iraq
3 Institute of Medical and Biomedical Education, St. George’s University of London, London, United Kingdom
Advanced Neurology 2023, 2(2), 378 https://doi.org/10.36922/an.378
Submitted: 15 February 2023 | Accepted: 2 May 2023 | Published: 25 May 2023
© 2023 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Download PDF
Cite
XML
Abstract

Idiopathic inflammatory myopathies, commonly known as myositis, are a diverse group of disorders defined clinically by persistent muscle weakness and reduced muscle endurance, as well as inflammatory cell infiltrates inside the muscle tissue. Myositis as a complication of coronavirus disease 2019 (COVID-19) has been described in an increasing number of reports. An analytical and cross-sectional study was undertaken in Basrah to analyze nerve conduction studies (NCS) and electromyographic (EMG) data in a COVID-19-affected patient. During the evaluation of 2240 patients, three cases of myositis were reported among the COVID-19 population, two of them with new clinical and EMG evidence of inflammatory myositis after the onset of COVID-19 infection, and one patient had a history of polymyositis before the COVID-19 pandemic, but a relapse was triggered by COVID-19, resulting in respiratory failure and death. The study found that the prevalence of myositis among the COVID-19 population was equal to 0.22%, which is 44 times higher than the prevalence of myositis (0.005%) worldwide before the onset of COVID-19 (P < 0.001).

Keywords
Inflammatory myopathy
Polymyositis
Dermatomyositis
COVID-19
Funding
None.
Conflict of interest
The authors declare that they have no competing interests.
References
  1. Hashim AR, Kadhum HJ, Farid HA, 2022, The pattern of Covid 19 among hospitalized athletics patient: A comparative study from Basrah city, Southern Iraq. J Res Med Dent Sci, 10: 36–40.

 

  1. Farid HA, Hashim AR, Hasrat NH, et al., 2021, The neurological manifestations of COVID-19 and their relationship with the disease severity in hospitalized patients: A single-centered, cross-sectional study on patients with COVID-19 from Basra, Iraq. Multicult Educ, 7: 391. https://doi.org/10.5281/zenodo.4730889

 

  1. Hasrat NH, Kadhum HJ, Hashim AR, et al., 2022, Neurographic evidence of inflammatory polyneuropathies in Peri-COVID-19 circumstances and their relationship with acute disease severity and inflammatory storm. Cureus, 14: e23517. https://doi.org/10.7759/cureus.23517

 

  1. Lundberg IE, Miller FW, Tjärnlund A, et al., 2016, Diagnosis and classification of idiopathic inflammatory myopathies. J Intern Med, 280: 39–51. https://doi.org/10.1111/joim.12524

 

  1. Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, et al., 2020. Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry. Neurology, 95: e1060–e1070. https://doi.org/10.1212/WNL.0000000000009937

 

  1. Taga A, Lauria G, 2022, COVID-19 and the peripheral nervous system. A 2-year review from the pandemic to the vaccine era. J Peripher Nerv Syst, 27: 4–30. https://doi.org/10.1111/jns.12482

 

  1. Hasrat NH, Kadhum HJ, Hashim AR, et al., 2022, Neurophysiological changes by nerve conduction study and electromyography in acute and long-term COVID-19 circumstances: A comparative study protocol and review. J Xian Shiyou Univ, 18: 241–249.

 

  1. Case Definition for Coronavirus Disease, 2019, (COVID-19), as of 3 December 2020. European Centre for Disease Prevention and Control. Available from: https://www.ecdc. europa.eu/en/covid-19/surveillance/case-definition [Last accessed on 2022 Jun 12].

 

  1. Preston D, Shapiro B, 2020, Electromyography and Neuromuscular Disorders: Clinical-Electrophysiologic Correlations. 4th ed. Amsterdam: Elsevier Saunders. Available from: https://www.elsevier.com/books/electromyography-and-neuromuscular-disorders/978-0-323-66180-5 [Last accessed on 2022 Dec 10].

 

  1. Anthony S, Phrathep DD, El-Husari A, et al., 2022, Post- COVID-19 polymyositis: A case report. Cureus, 14: e30991. https://10.7759/cureus.30991

 

  1. Hunter K, Lyon MG, 2012, Evaluation and management of polymyositis. Indian J Dermatol, 57: 371–374. https://doi.org/10.4103/0019-5154.100479

 

  1. Gokhale Y, Patankar A, Holla U, et al., 2020, Dermatomyositis during COVID-19 pandemic (A case series): Is there a cause effect relationship? J Assoc Physicians India, 68: 20–24.

 

  1. Movahedi N, Ziaee V, 2021, COVID-19 and myositis; true dermatomyositis or prolonged post viral myositis? Pediatr Rheumatol Online J, 19: 86. https://doi.org/10.1186/s12969-021-00570-w

 

  1. Saud A, Naveen R, Aggarwal R, et al., 2021, COVID-19 and myositis: What we know so far. Curr Rheumatol Rep, 23: 63. https://doi.org/10.1007/s11926-021-01023-9

 

  1. Naveen R, Sundaram TG, Agarwal V, et al., 2021, Teleconsultation experience with the idiopathic inflammatory myopathies: A prospective observational cohort study during the COVID-19 pandemic. Rheumatol Int, 41: 67–76. https://doi.org/10.1007/s00296-020-04737-8

 

  1. Venalis P, Lundberg IE, 2014, Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy. Rheumatology (Oxford), 53: 397–405. https://doi.org/10.1093/rheumatology/ket279

 

  1. Albakri AM, Subki AH, Albeity A, et al., 2022, Dermatomyositis flare after a COVID-19 infection successfully treated with rituximab: A case report and literature review. J Inflamm Res, 15: 6047–6053. https://doi.org/10.2147/JIR.S369477

 

  1. Cheeti A, Brent LH, Panginikkod S, 2022, Autoimmune myopathies. In: StatPearls. Treasure Island, FL: StatPearls Publishing.

 

  1. Amin S, Rahim F, Noor M, et al., 2022, Polymyositis: The comet tail after COVID-19. Cureus, 14: e26453. https://doi.org/10.7759/cureus.26453

 

  1. Gracia-Ramos AE, Martin-Nares E, Hernández-Molina G, 2021 New onset of autoimmune diseases following COVID-19 diagnosis. Cells, 10: 3592. https://doi.org/10.3390/cells10123592

 

  1. Ochani R, Asad A, Yasmin F, et al., 2021, COVID-19 pandemic: From origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management. Infez Med, 29: 20–36.

 

  1. Anka AU, Tahir MI, Abubakar SD, et al., 2021, Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management. Scand J Immunol, 93: e12998. https://doi.org/10.1111/sji.12998

 

  1. Li YC, Bai WZ, Hashikawa T, 2020, The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol, 92: 552–555. https://doi.org/10.1002/jmv.25728

 

  1. Zubair AS, McAlpine LS, Gardin T, et al., 2020, Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: A review. JAMA Neurol, 77: 1018–1027. https://doi.org/10.1001%2Fjamaneurol.2020.2065

 

  1. Canetta C, Accordino S, Buscarini E, et al., 2020, Syncope at SARS-CoV-2 onset. Auton Neurosci, 229: 102734. https://doi.org/10.1016%2Fj.autneu.2020.102734

 

  1. Batchu S, Diaz MJ, Tran JT, et al., 2023, Spatial mapping of genes implicated in SARS-CoV-2 neuroinvasion to dorsolateral prefrontal cortex gray matter. COVID, 3: 82–89. https://doi.org/10.3390/covid3010005

 

  1. Sizemore G, Lucke-Wold B, Small C, 2022, Review of SARS-COV-2 systemic impact: Building the case for sepsis via virus in the circulatory system. SM J Neurol Disord Stroke, 6: 7.

 

  1. Small C, Mehkri Y, Panther E, et al., 2020, Coronavirus disease-2019 and stroke: Pathophysiology and management. Can J Neurol Sci, 28: 1–8. https://doi.org/10.1017/cjn.2022.267
Share
Back to top
Advanced Neurology, Electronic ISSN: 2810-9619 Print ISSN: 3060-8589, Published by AccScience Publishing
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept